Taiyen Biotech Co Ltd (1737) - Total Liabilities
Based on the latest financial reports, Taiyen Biotech Co Ltd (1737) has total liabilities worth NT$1.45 Billion TWD (≈ $45.64 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Taiyen Biotech Co Ltd to assess how effectively this company generates cash.
Taiyen Biotech Co Ltd - Total Liabilities Trend (2003–2025)
This chart illustrates how Taiyen Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Taiyen Biotech Co Ltd to evaluate the company's liquid asset resilience ratio.
Taiyen Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Taiyen Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yantai Changyu Pioneer Wine
SHE:200869
|
China | HK$1.48 Billion |
|
Maritime Resources Corp.
V:MAE
|
Canada | CA$18.32 Million |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
Switzerland | CHF102.51 Million |
|
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
|
USA | $511.24K |
|
Jw Holdings
KO:096760
|
Korea | ₩662.18 Billion |
|
RCI Hospitality Holdings Inc
NASDAQ:RICK
|
USA | $328.11 Million |
|
X-Legend Entertainment Co Ltd
TW:4994
|
Taiwan | NT$435.07 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Taiyen Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Taiyen Biotech Co Ltd (1737) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Taiyen Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Taiyen Biotech Co Ltd (2003–2025)
The table below shows the annual total liabilities of Taiyen Biotech Co Ltd from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$1.45 Billion ≈ $45.64 Million |
-15.45% |
| 2024-12-31 | NT$1.71 Billion ≈ $53.99 Million |
-3.24% |
| 2023-12-31 | NT$1.77 Billion ≈ $55.79 Million |
+14.27% |
| 2022-12-31 | NT$1.55 Billion ≈ $48.83 Million |
-20.70% |
| 2021-12-31 | NT$1.95 Billion ≈ $61.57 Million |
+36.33% |
| 2020-12-31 | NT$1.43 Billion ≈ $45.16 Million |
-1.05% |
| 2019-12-31 | NT$1.45 Billion ≈ $45.64 Million |
+23.77% |
| 2018-12-31 | NT$1.17 Billion ≈ $36.87 Million |
-4.74% |
| 2017-12-31 | NT$1.23 Billion ≈ $38.71 Million |
+15.14% |
| 2016-12-31 | NT$1.07 Billion ≈ $33.62 Million |
+7.77% |
| 2015-12-31 | NT$990.08 Million ≈ $31.19 Million |
+8.42% |
| 2014-12-31 | NT$913.15 Million ≈ $28.77 Million |
+109.12% |
| 2013-12-31 | NT$436.66 Million ≈ $13.76 Million |
+27.49% |
| 2012-12-31 | NT$342.49 Million ≈ $10.79 Million |
-3.94% |
| 2011-12-31 | NT$356.53 Million ≈ $11.23 Million |
-3.47% |
| 2010-12-31 | NT$369.36 Million ≈ $11.64 Million |
+12.23% |
| 2009-12-31 | NT$329.10 Million ≈ $10.37 Million |
+7.40% |
| 2008-12-31 | NT$306.42 Million ≈ $9.65 Million |
-16.72% |
| 2007-12-31 | NT$367.92 Million ≈ $11.59 Million |
-25.99% |
| 2006-12-31 | NT$497.10 Million ≈ $15.66 Million |
-46.31% |
| 2005-12-31 | NT$925.79 Million ≈ $29.17 Million |
-53.50% |
| 2004-12-31 | NT$1.99 Billion ≈ $62.73 Million |
-52.17% |
| 2003-12-31 | NT$4.16 Billion ≈ $131.13 Million |
-- |
About Taiyen Biotech Co Ltd
Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. It offers beauty and skincare, and cleaning products; salt products; and leisure and pet foods, as well as health supplement. The company was founded in 1952 and is based in Tainan City, Taiwan.